Welcome to Iris Biotech
For better service please confirm your country and language we detected.
For better service please confirm your country and language we detected.
Thank you very much for your interest in our products. All prices listed on our website are ex-works, Germany, and may attract customs duties when imported.
You may/will be contacted by the shipping company for additional documentation that may be required by the US Customs for clearance.
We offer you the convenience of buying through a local partner, Peptide Solutions LLC who can import the shipment as well as prepay the customs duties and brokerage on your behalf and provide the convenience of a domestic sale.
Continue to Iris Biotech GmbHSend request to US distributorSynonyme: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methyle thyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-2
Startet von 350,00 €
Rapamycin inhibits angiogenesis - a new candidate for combination therapy!
Rapamycin, approved by the FDA for immunosuppression in transplant patients, is currently under investigation for cancer treatment. It inhibits endothelial Akt signaling, vascular changes from myrAkt1, tumor growth, and tumor vascular permeability. In mouse models a reduced tumor growth and vascular leak has been observed. These findings make rapamycin very interesting in regimens where anti-angiogenic therapy in cancer patients is desired.
Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.
Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC,
Dvorak HF, Benjamin LE; Cancer Cell. 2006; 10(2): 159-70.
Sie benötigen größere Mengen für Ihre Entwicklung oder Produktion?
Bitte senden Sie mir mehr Informationen über